Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Total Current Liabilities (2019 - 2025)

BridgeBio Pharma (BBIO) has disclosed Total Current Liabilities for 7 consecutive years, with $288.0 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 86.51% to $288.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $288.0 million through Dec 2025, up 86.51% year-over-year, with the annual reading at $288.0 million for FY2025, 86.51% up from the prior year.
  • Total Current Liabilities hit $288.0 million in Q4 2025 for BridgeBio Pharma, up from $216.6 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $288.0 million in Q4 2025 to a low of $94.7 million in Q1 2021.
  • Historically, Total Current Liabilities has averaged $140.1 million across 5 years, with a median of $134.7 million in 2021.
  • Biggest five-year swings in Total Current Liabilities: decreased 21.99% in 2023 and later surged 86.51% in 2025.
  • Year by year, Total Current Liabilities stood at $135.1 million in 2021, then dropped by 10.1% to $121.4 million in 2022, then increased by 18.46% to $143.8 million in 2023, then rose by 7.34% to $154.4 million in 2024, then skyrocketed by 86.51% to $288.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for BBIO at $288.0 million in Q4 2025, $216.6 million in Q3 2025, and $175.9 million in Q2 2025.